These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9602985)

  • 21. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study.
    Vejdani R; Shalmani HR; Mir-Fattahi M; Sajed-Nia F; Abdollahi M; Zali MR; Mohammad Alizadeh AH; Bahari A; Amin G
    Dig Dis Sci; 2006 Aug; 51(8):1501-7. PubMed ID: 16868824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
    Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
    Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome.
    Schütze K; Brandstätter G; Dragosics B; Judmaier G; Hentschel E
    Aliment Pharmacol Ther; 1997 Apr; 11(2):387-94. PubMed ID: 9146780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
    Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
    Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome.
    Pineton de Chambrun G; Neut C; Chau A; Cazaubiel M; Pelerin F; Justen P; Desreumaux P
    Dig Liver Dis; 2015 Feb; 47(2):119-24. PubMed ID: 25488056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
    Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW; Stanghellini V; Geraint M; Halphen M
    Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
    Simrén M; Simms L; D'Souza D; Abrahamsson H; Björnsson ES
    Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study.
    Baldi F; Longanesi A; Blasi A; Monello S; Cestari R; Missale G; Corazziari E; Badiali G; Marzio L; Di Felice F
    Hepatogastroenterology; 1992 Oct; 39(5):392-5. PubMed ID: 1459516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients?
    Sach J; Bolus R; Fitzgerald L; Naliboff BD; Chang L; Mayer EA
    Am J Gastroenterol; 2002 Dec; 97(12):3131-8. PubMed ID: 12492200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
    Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
    Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome.
    Stevenson C; Blaauw R; Fredericks E; Visser J; Roux S
    Nutrition; 2014 Oct; 30(10):1151-7. PubMed ID: 25194614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
    Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome.
    Wouters MM; Balemans D; Van Wanrooy S; Dooley J; Cibert-Goton V; Alpizar YA; Valdez-Morales EE; Nasser Y; Van Veldhoven PP; Vanbrabant W; Van der Merwe S; Mols R; Ghesquière B; Cirillo C; Kortekaas I; Carmeliet P; Peetermans WE; Vermeire S; Rutgeerts P; Augustijns P; Hellings PW; Belmans A; Vanner S; Bulmer DC; Talavera K; Vanden Berghe P; Liston A; Boeckxstaens GE
    Gastroenterology; 2016 Apr; 150(4):875-87.e9. PubMed ID: 26752109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.
    Glende M; Morselli-Labate AM; Battaglia G; Evangelista S
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.